Intelligent Bio Solutions Inc. INBS 深 沪
等待开盘 04-02 09:30:00 美东时间
3.36
+0.015
+0.45%
华盛通- 最 高3.42
- 今 开3.42
- 成交量 2.38万股
- 最 低 3.1816
- 昨 收 3.345
- 总市值 672.39万
- 52周最高 24.90
- 市盈率 静 --
- 换手率 1.19%
- 52周最低 2.86
- 委 比 0.00%
- 总股本 200.12万
- 历史最高 34176.00
- 量 比 1.70
- 振 幅 7.13%
- 历史最低 2.86
- 每 手 1
- 风险率 4.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant
Intelligent Bio Solutions Inc. (INBS) announced the grant of its eighth European patent, EP3752831, which protects advancements in contextualizing fingerprint chemical analysis with fingerprint deposition volume. This innovation enhances the interpretation of substances detected in fingerprint sweat and strengthens the robustness of the testing process, further reinforcing INBS' market position and intellectual property portfolio in Europe. The p...
03-26 12:30
Intelligent Bio Solutions Partners With Bouygues UK For Deployment Of INBS's Fingerprint Drug Screening Technology Across Its UK Operations
Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a partnership with Bouygues UK, a
02-24 21:47
Intelligent Bio Solutions Partners With Bouygues UK for Fingerprint Drug Testing Rollout
Intelligent Bio Solutions Partners With Bouygues UK for Fingerprint Drug Testing Rollout Intelligent Bio Solutions Inc. has partnered with Bouygues UK, a subsidiary of Bouygues Construction, to roll out its fingerprint drug screening technology across Bouygues UK’s operations. The initial deployment
02-24 21:45
Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Billion Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout
Intelligent Bio Solutions Inc. (INBS) has partnered with Bouygues UK, a subsidiary of Bouygues Construction, to deploy its fingerprint drug testing technology across 13 UK project sites. This collaboration demonstrates the commercial scalability and ROI of INBS's technology, offering a hygienic, efficient, and cost-effective solution compared to third-party services. Bouygues Construction, a global leader with operations in over 50 countries, tra...
02-24 13:45
Intelligent Bio Solutions Q2 EPS $(2.82) Up From $(4.96) YoY, Sales $896.774K Up From $607.494K YoY
Intelligent Bio Solutions (NASDAQ:INBS) reported quarterly losses of $(2.82) per share. This is a 43.15 percent increase over losses of $(4.96) per share from the same period last year. The company reported $896.774
02-12 22:18
INBS Q2 reader sales double to USD 1.04 million
INBS Q2 reader sales double to USD 1.04 million Intelligent Bio Solutions Inc. (INBS) reported fiscal second quarter results with revenue growth of 48% year-over-year. For the first half of fiscal 2026, revenue surpassed USD 2 million, representing a 36% increase compared to the previous year. Reade
02-12 21:30
Intelligent Bio Solutions Expects Fiscal Q2 2026 Revenue to Surge 48% Year-Over-Year
Intelligent Bio Solutions Expects Fiscal Q2 2026 Revenue to Surge 48% Year-Over-Year Intelligent Bio Solutions Inc. expects to report strong financial results for its fiscal second quarter and first half of 2026, ended December 31, 2025. The company anticipates total revenue of approximately $2.01 m
02-05 21:54
Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market
Intelligent Bio Solutions Inc. has launched a clinical study program to support its FDA 510(k) application for the U.S. market clearance of its fingerprint-based drug screening system for detecting codeine. Partnering with Cliantha Research, the first study will enroll 40 adults to establish optimal detection thresholds, with results expected by March 2026. The U.S. drug screening market, valued at several billion dollars annually, presents a sig...
01-28 13:30
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers PAVmed (NASDAQ:PAVM) stock increased by 250.7% to $21.71 during Wednes...
01-22 01:05
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers NovaBay Pharmaceuticals (AMEX:NBY) stock rose 36.9% to $12.95 during F...
01-10 01:05
